BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34644566)

  • 1. Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms.
    Yang KC; Kalloger SE; Aird JJ; Lee MKC; Rushton C; Mungall KL; Mungall AJ; Gao D; Chow C; Xu J; Karasinska JM; Colborne S; Jones SJM; Schrader J; Morin RD; Loree JM; Marra MA; Renouf DJ; Morin GB; Schaeffer DF; Gorski SM
    Cell Rep; 2021 Oct; 37(2):109817. PubMed ID: 34644566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms.
    Vandamme T; Beyens M; Boons G; Schepers A; Kamp K; Biermann K; Pauwels P; De Herder WW; Hofland LJ; Peeters M; Van Camp G; Op de Beeck K
    Endocr Relat Cancer; 2019 Jan; 26(1):1-12. PubMed ID: 30021865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
    Luchini C; Lawlor RT; Bersani S; Vicentini C; Paolino G; Mattiolo P; Pea A; Cingarlini S; Milella M; Scarpa A
    Curr Oncol Rep; 2021 Jul; 23(9):106. PubMed ID: 34269919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropilin-1 (NRP-1) upregulated by IL-6/STAT3 signaling contributes to invasion in pancreatic neuroendocrine neoplasms.
    Yang Y; Yang L; Li Y
    Hum Pathol; 2018 Nov; 81():192-200. PubMed ID: 30420046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors.
    Chatani PD; Agarwal SK; Sadowski SM
    Front Endocrinol (Lausanne); 2020; 11():575620. PubMed ID: 33537001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor.
    Quevedo R; Spreafico A; Bruce J; Danesh A; El Ghamrasni S; Giesler A; Hanna Y; Have C; Li T; Yang SYC; Zhang T; Asa SL; Haibe-Kains B; Krzyzanowska M; Smith AC; Singh S; Siu LL; Pugh TJ
    Genome Med; 2020 Apr; 12(1):38. PubMed ID: 32345369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.
    Sadanandam A; Wullschleger S; Lyssiotis CA; Grötzinger C; Barbi S; Bersani S; Körner J; Wafy I; Mafficini A; Lawlor RT; Simbolo M; Asara JM; Bläker H; Cantley LC; Wiedenmann B; Scarpa A; Hanahan D
    Cancer Discov; 2015 Dec; 5(12):1296-313. PubMed ID: 26446169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences between Well-Differentiated Neuroendocrine Tumors and Ductal Adenocarcinomas of the Pancreas Assessed by Multi-Omics Profiling.
    Starzyńska T; Karczmarski J; Paziewska A; Kulecka M; Kuśnierz K; Żeber-Lubecka N; Ambrożkiewicz F; Mikula M; Kos-Kudła B; Ostrowski J
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32586046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic Hedgehog-Smoothened Signaling Depends on YAP1‒TAZ/TEAD Transcription to Restrain Differentiation in Basal Cell Carcinoma.
    Yuan Y; Salinas Parra N; Chen Q; Iglesias-Bartolome R
    J Invest Dermatol; 2022 Jan; 142(1):65-76.e7. PubMed ID: 34293352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours.
    Pipinikas CP; Dibra H; Karpathakis A; Feber A; Novelli M; Oukrif D; Fusai G; Valente R; Caplin M; Meyer T; Teschendorff A; Bell C; Morris TJ; Salomoni P; Luong TV; Davidson B; Beck S; Thirlwell C
    Endocr Relat Cancer; 2015 Jun; 22(3):L13-8. PubMed ID: 25900181
    [No Abstract]   [Full Text] [Related]  

  • 11. Upregulated microRNA let-7a accelerates apoptosis and inhibits proliferation in uterine junctional zone smooth muscle cells in adenomyosis under conditions of a normal activated hippo-YAP1 axis.
    Huang JH; Duan H; Wang S; Wang YY; Lv CX
    Reprod Biol Endocrinol; 2021 Jun; 19(1):81. PubMed ID: 34082774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event.
    Knösel T; Chen Y; Altendorf-Hofmann A; Danielczok C; Freesmeyer M; Settmacher U; Wurst C; Schulz S; Yang LL; Petersen I
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):397-403. PubMed ID: 22160160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors.
    Hackeng WM; Assi HA; Westerbeke FHM; Brosens LAA; Heaphy CM
    Surg Pathol Clin; 2022 Sep; 15(3):541-554. PubMed ID: 36049835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain.
    Bartsch DK; Slater EP; Albers M; Knoop R; Chaloupka B; Lopez CL; Fendrich V; Kann PH; Waldmann J
    J Clin Endocrinol Metab; 2014 Nov; 99(11):E2387-91. PubMed ID: 25210877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YAP facilitates melanoma migration through regulation of actin-related protein 2/3 complex subunit 5 (ARPC5).
    Lui JW; Moore SPG; Huang L; Ogomori K; Li Y; Lang D
    Pigment Cell Melanoma Res; 2022 Jan; 35(1):52-65. PubMed ID: 34468072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. lncRNA H19 binds VGF and promotes pNEN progression via PI3K/AKT/CREB signaling.
    Ji M; Yao Y; Liu A; Shi L; Chen D; Tang L; Yang G; Liang X; Peng J; Shao C
    Endocr Relat Cancer; 2019 Jul; 26(7):643-658. PubMed ID: 31117050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
    Jiao Y; Shi C; Edil BH; de Wilde RF; Klimstra DS; Maitra A; Schulick RD; Tang LH; Wolfgang CL; Choti MA; Velculescu VE; Diaz LA; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N
    Science; 2011 Mar; 331(6021):1199-203. PubMed ID: 21252315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular subtyping in pancreatic neuroendocrine neoplasms: New insights into clinical, pathological unmet needs and challenges.
    Yan J; Yu S; Jia C; Li M; Chen J
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188367. PubMed ID: 32339609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis.
    Duerr EM; Mizukami Y; Ng A; Xavier RJ; Kikuchi H; Deshpande V; Warshaw AL; Glickman J; Kulke MH; Chung DC
    Endocr Relat Cancer; 2008 Mar; 15(1):243-56. PubMed ID: 18310291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDZ-binding kinase aggravates pancreatic neuroendocrine neoplasm progression by activating the AKT/mTOR pathway.
    Feng T; Jiang R; Yin L; Xu C; Ma J; Yin W; Jin J; Lu T; Liu X; Lyu Y; Yang Y; Ying L; Hu Q; Su D; Ling S
    Mol Carcinog; 2023 May; 62(5):716-726. PubMed ID: 36807309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.